3.15

1.56% -0.05

Ovid Therapeutics Inc (OVID)

Overview News Price History Option Chain Discussions Forecast

Ovid Therapeutics Inc stock is currently priced at $3.15, with a 24-hour trading volume of 111.25K. It has seen a -1.56% decreased in the last 24 hours and a -1.56% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.18 pivot point. If it approaches the $3.13 support level, significant changes may occur.

Previous Close:

$3.20

Open:

$3.18

24h Volume:

111.25K

Market Cap:

$222.74M

Revenue:

$391.70K

Net Income/Loss:

$-52.34M

P/E Ratio:

-4.50

EPS:

-0.7

Net Cash Flow:

$-45.92M

1W Performance:

+1.29%

1M Performance:

-1.56%

6M Performance:

-12.74%

1Y Performance:

-5.41%

1D Range:

$3.11

$3.216

52W Range:

$2.57

$4.1389

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name

Ovid Therapeutics Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

646-661-7661

Address

1460 Broadway, Suite 15044, New York, NY

Employee

Twitter

@OvidRx

Next Earnings Date

2024-05-03

Latest SEC Filings

OVID's Discussions on Twitter

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-21	Downgrade	Cantor Fitzgerald	Buy → Neutral
Mar-03-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-02-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-19	Initiated	RBC Capital Mkts	Outperform
Apr-20-18	Initiated	Ladenburg Thalmann	Buy

View All

Ovid Therapeutics Inc Stock (OVID) Latest News

Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Benzinga

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire Inc.

Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress

Zacks Investment Research

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

Zacks Investment Research

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

GlobeNewswire Inc.

Ovid Therapeutics Inc Stock (OVID) Financials Data

Ovid Therapeutics Inc (OVID) Revenue 2024

OVID reported a revenue (TTM) of $391.70 thousand for the quarter ending December 31, 2023.

Ovid Therapeutics Inc (OVID) Net Income 2024

OVID net income (TTM) was -$52.34 million for the quarter ending December 31, 2023, a +3.38% increase year-over-year.

Ovid Therapeutics Inc (OVID) Cash Flow 2024

OVID recorded a free cash flow (TTM) of -$45.92 million for the quarter ending December 31, 2023, a +18.94% increase year-over-year.

Ovid Therapeutics Inc (OVID) Earnings per Share 2024

OVID earnings per share (TTM) was -$0.75 for the quarter ending December 31, 2023, a +2.60% growth year-over-year.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.